Samsung Medison
As of this moment when a half of the year has passed, Samsung Medison earnings are getting worse. Its sales, which recorded a 26.9 billion won (US$23.4 million) loss last year, are more shrinking than that of last year, leading to more deficits.
According to industry sources on August 22, the medical equipment maker had 119.4 billion won (US$103.8 million) in sales and 18.4 billion (US$16.0 million) in the operating loss in the first half of this year. When the figures are compared to 139.3 billion won (US$121.1 million) in sales and 8.1 billion won (US$7.04 million) in operating loss recorded in the first half of last year, the company has shown a poor performance with weaker in sales and profits alike.
Samsung Medison now carries out a project exploring new business while improving the efficiency of its business. It has devoted to expanding a market for animal diagnostic devices used to diagnose diseases like a cardiac disorder with the blood of dogs, cats, and horses, and has recently unveiled a deep learning-based ultrasound imaging device.
The company has also rearranged its overseas operating network, with more than 10 overseas branches closed except for only one in India. The effort aims at reducing costs while enhancing the marketing effectiveness by sharing the overseas operating network of Samsung Electronics.
Industry insiders agree that it is time for Samsung Medison to make a breakthrough. It means that the firm must make premium-level products by making efforts to secure technologies. Some say that the development of core technologies has been slower since Samsung took over Medison in 2011. Samsung Medison has been in deficit after it marked an operating loss of 26.9 billion won (US$23.4 million) last year. This is why there is a rumor circulating in the industry at every opportunity that the company might be merged into Samsung Electronics or might be sold.